This article discusses the AI-driven pharmaceutical company Generate, which has raised $2.73 billion in funding. The company plans to use this capital to support its drug development efforts across various disease areas, including cancer, infectious diseases, and immune disorders. Generate replaces the trial-and-error approach to drug discovery with AI and creates novel protein-based therapies. Additionally, Generate is testing a monoclonal antibody therapy for treating COVID-19, marking the company's first treatment to enter human trials. The company states that the latest round of financing will help enhance the precision, speed, and likelihood of success in drug development. This Series C funding round has attracted new investors in addition to existing ones.